CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $10.24B, above the global median of $1.18B
- PositionOperating margin is 49%, higher than 95% of its Biotechnology peers (median -38%)
- Interpretations11 currently firing — 11
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
10.24BUSDvs all stocks (USD)
Trailing P/E
43.28xvs Biotechnology peers
Revenue (TTM)
440.48MUSDvs all stocks (USD)
Profit Margin
54.82%vs Biotechnology peers
Beta
0.5370xvs all stocks
52-Week Change
95.66%vs all stocks
Market Capitalization
10.24BUSDvs all stocks (USD)
Enterprise Value
9.40BUSDvs all stocks (USD)
Trailing P/E
43.28xvs Biotechnology peers
Forward P/E
37.11xvs Biotechnology peers
PEG Ratio
1.11xvs Biotechnology peers
Price to Sales (TTM)
23.24xvs Biotechnology peers
Price to Book (MRQ)
7.53xvs Biotechnology peers
Enterprise to Revenue
21.34xvs Biotechnology peers
Enterprise to EBITDA
47.16xvs Biotechnology peers
Gross Margin
94.60%vs Biotechnology peers
Profit Margin
54.82%vs Biotechnology peers
Operating Margin
49.00%vs Biotechnology peers
Return on Assets (TTM)
9.37%vs Biotechnology peers
Return on Equity (TTM)
20.12%vs Biotechnology peers
Revenue (TTM)
440.48MUSDvs all stocks (USD)
Revenue per Share (TTM)
15.08USDUpdated Sep 27, 2026Quarterly Revenue Growth
24.10%vs Biotechnology peers
Gross Profit (TTM)
416.87MUSDvs all stocks (USD)
EBITDA (TTM)
204.42MUSDvs all stocks (USD)
Net Income (TTM)
241.46MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
42.90%vs Biotechnology peers
Operating Cash Flow (TTM)
272.34MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
151.74MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
389.13MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
23.05MUSDFY2025 · Dec 31, 2025Gross Profit
366.08MUSDFY2025 · Dec 31, 2025Operating Income
161.29MUSDvs all stocks (USD)
Pre-tax Income
189.47MUSDFY2025 · Dec 31, 2025Income Tax Expense
-15.36MUSDFY2025 · Dec 31, 2025Net Income
204.83MUSDFY2025 · Dec 31, 2025EBIT
161.29MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
167.85MUSDFY2025 · Dec 31, 2025Research & Development
58.05MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
146.74MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
28.18MUSDFY2025 · Dec 31, 2025EPS (Basic)
7.08USDFY2025 · Dec 31, 2025EPS (Diluted)
6.84USDFY2025 · Dec 31, 2025Basic Shares Outstanding
28.94MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
28.94MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
204.83MUSDFY2025 · Dec 31, 2025Operating Cash Flow
217.85MUSDFY2025 · Dec 31, 2025Free Cash Flow
205.90MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
496.30MUSDFY2025 · Dec 31, 2025Income Tax Paid
15.67MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
204.83MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
6.55MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-22.84MUSDFY2025 · Dec 31, 2025Stock-based Compensation
54.51MUSDFY2025 · Dec 31, 2025Other Non-cash Items
684.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-22.12MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
826.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-4.58MUSDFY2025 · Dec 31, 2025Capital Expenditures
-11.95MUSDFY2025 · Dec 31, 2025Purchase of Investments
-422.54MUSDFY2025 · Dec 31, 2025Sale of Investments
375.64MUSDFY2025 · Dec 31, 2025Other Investing Activity
435.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-58.42MUSDFY2025 · Dec 31, 2025Other Financing Charges
-13.96MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-13.96MUSDFY2025 · Dec 31, 2025Shares Outstanding
29.60MSharesUpdated Sep 27, 2026Float Shares
23.62MSharesUpdated Sep 27, 2026Shares Short
3.16MSharesUpdated Sep 27, 2026Short Ratio
13.65daysvs all stocks
Short % of Shares Outstanding
17.50%vs all stocks
% Held by Insiders
10.66%vs all stocks
% Held by Institutions
102.53%vs all stocks
Total Cash (MRQ)
845.63MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
28.57USDUpdated Sep 27, 2026Total Debt (MRQ)
8.85MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0065xvs Biotechnology peers
Current Ratio (MRQ)
8.32xvs Biotechnology peers
Book Value per Share (MRQ)
45.92USDUpdated Sep 27, 2026Total Assets
1.33BUSDvs all stocks (USD)
Total Current Assets
1.02BUSDFY2025 · Dec 31, 2025Total Liabilities
114.23MUSDFY2025 · Dec 31, 2025Total Non-current Assets
309.19MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
11.29MUSDFY2025 · Dec 31, 2025Total Current Liabilities
102.94MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
496.30MUSDFY2025 · Dec 31, 2025Other Short-term Investments
331.49MUSDFY2025 · Dec 31, 2025Accounts Receivable
127.42MUSDFY2025 · Dec 31, 2025Inventory
40.48MUSDFY2025 · Dec 31, 2025Accounts Payable
3.24MUSDFY2025 · Dec 31, 2025Short-term Debt
1.77MUSDFY2025 · Dec 31, 2025Other Current Liabilities
3.58MUSDFY2025 · Dec 31, 2025Long-term Debt
7.57MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
3.72MUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
24.16MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.22BUSDvs all stocks (USD)
52-Week Low
168.34USDUpdated Sep 27, 202652-Week High
382.54USDUpdated Sep 27, 202652-Week Change
95.66%vs all stocks
Beta
0.5370xvs all stocks
50-Day MA
343.33USDUpdated Sep 27, 2026200-Day MA
299.16USDUpdated Sep 27, 2026Avg 10-Day Volume
317.41KSharesUpdated Sep 27, 2026Avg 30-Day Volume
256.52KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
7.99USDUpdated Sep 27, 202611 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
Is this company growing?
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
Where is this company structurally exposed?
SBC-to-Net-Income Elevated, SBC-to-Revenue Elevated, And Diluted Share Count Growing (6Y CAGR)
Pay in shares is large next to its revenue and its profit, and the share count keeps rising.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 49%, higher than 95% of its Biotechnology peers (median -38%)Significant
Operating margin: 0.49Industry median: -0.38Industry P95: 0.40Peers compared: 260
Profit margin is 54.8%, higher than 95% of its Biotechnology peers (median -47.7%)Significant
Profit margin: 0.55Industry median: -0.48Industry P95: 0.42Peers compared: 260
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $10.24B, above the global median of $1.18BNotable
Market cap (USD): 10,235,869,761Global Median: 1,180,223,658.953
Levered free cash flow is $151.74M, above the global median of $18.73MNotable
Levered free cash flow (USD): 151,739,744Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Apogee Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Axsome Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bio-Rad Laboratories Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Asymchem Laboratories (Tianjin) Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Lupin Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Globus Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
RemeGen Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Dr. Reddy's Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nuvalent, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bruker Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Global Ship Lease Inc.
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragCash Backing With Revenue And Income StreaksFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
United States Lime & Minerals Inc.
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Euroseas Ltd.
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragCash Backing With Revenue And Income StreaksFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels